Effects of Liraglutide on Cardiovascular Risk in Type 2 Diabetes
Author Information
Author(s): Courrèges J-P, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S
Primary Institution: Centre Hospitalier de Narbonne
Hypothesis
Does liraglutide improve cardiovascular risk biomarkers in patients with Type 2 diabetes?
Conclusion
Liraglutide treatment resulted in significant decreases in certain cardiovascular risk biomarkers in patients with Type 2 diabetes.
Supporting Evidence
- Liraglutide significantly decreased PAI-1 and BNP levels.
- There was a non-significant reduction in hs-CRP levels.
- Subjects were previously treated with diet, exercise, or oral glucose-lowering agents.
- The study was part of a larger trial showing improved glycemic control.
- Significant reductions in systolic blood pressure and plasma triglycerides were observed.
Takeaway
Liraglutide helps lower some heart-related risks for people with diabetes when they take it every day.
Methodology
Patients were randomized to receive either placebo or different doses of liraglutide for 14 weeks, with various cardiovascular biomarkers assessed.
Potential Biases
Potential conflicts of interest due to funding and employment of some authors by Novo Nordisk.
Limitations
The study was not powered to detect significant differences in cardiovascular biomarkers.
Participant Demographics
Patients had a mean BMI of 28.9–31.2 kg/m2 and mean HbA1c of 8.1–8.5%.
Statistical Information
P-Value
0.018, 0.045
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website